Severe infusion reactions to fabry enzyme replacement therapy: Rechallenge after tracheostomy

JIMD Reports

Volumn 5, Issue , 2012, Pages 109-112

  Nicholls, K ^a,b   Bleasel, K ^a,b   Becker, G ^a,b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Agalsidase alfa; Enzyme replacement therapy; Fabry disease; Infusion reaction; Obstructive sleep apnoea

Indexed keywords

EID: 84978223267     PISSN: 21928304     EISSN: 21928312     Source Type: Book Series    
DOI: 10.1007/8904_2011_106     Document Type: Chapter

References (7)

1. Barbey F, Livio F (2006) Safety of enzyme replacement therapy. In: Mehta A, Beck M, Sunder-Plassmann G (eds) Fabry disease: perspectives from 5 years of FOS. Oxford PharmaGenesis, Oxford, Chapter 41. http://www.ncbi.nlm.nih.gov/books/NBK11617/
2. Eng CM, Guffon N, Wilcox WR et al (2001a) Safety and efficacy of recombinant human a-galactosidase A – replacement therapy in Fabry's disease. N Engl J Med 345:9–16
3. Eng CM, Banikazemi M, Gordon RE et al (2001b) A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68:711–722
4. Linthorst GE, Hollack CEM, Donker-Koopman WE, Strijland A, Aerts JMFG (2004) Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alfa and beta. Kidney Int 66:1589–1595
5. Ramaswami U, Wendt S, Parini R et al (2005) Safety of enzyme replacement therapy with agalsidase alfa in children with Fabry disease. J Inherit Metab Dis 28(Suppl 1):330
6. Schellekens H (2002) Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 1:457–462
7. Wilcox WR, Banikazemi M, Guffon N et al (2004) International Fabry Disease Study Group. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75:65–74